Imbrium Therapeutics and Mundipharma EDO Announce Orphan Drug Designation for Relapsed Refractory Biliary Tract Cancer Treatment

Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, announced on 2/21/19 that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its investigational drug etoposide toniribate, a novel topoisomerase II inhibitor, for the treatment of relapsed refractory biliary tract cancer.